<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="Vaccine Effectiveness During the Influenza Seasons 2016/17 to 2018/19 in" exact="Austria" post="Redlberger-FritzMonika1*KundiMichael2Popow-KrauppTherese1[], 1Centre of Virology, Medical University ViennaViennaAustria[], 2Department of"/>
 <result pre="ViennaViennaAustria Edited by: Rita Carsetti, Bambino GesÃ¹ Children Hospital (IRCCS)," exact="Italy" post="Reviewed by: Raffael Nachbagauer, Icahn School of Medicine at"/>
 <result pre="by: Raffael Nachbagauer, Icahn School of Medicine at Mount Sinai," exact="United States;" post="Rong Hai, University of California, Riverside, United States *Correspondence:"/>
 <result pre="Mount Sinai, United States; Rong Hai, University of California, Riverside," exact="United States" post="*Correspondence: Monika Redlberger-Fritz monika.redlberger@meduniwien.ac.at This article was submitted to"/>
 <result pre="pediatricians throughout Austria) forming part of the Diagnostic Influenza Network" exact="Austria" post="(DINOE), who collect nasopharyngeal swabs from patients presenting with"/>
 <result pre="(6). Vaccination Available influenza vaccines for the season 2016/17 in" exact="Austria" post="were: TIV and aTIV containing the following recommended vaccine"/>
 <result pre="season 2017/18 quadrivalent inactivated influenza vaccines (QIV) were available in" exact="Austria" post="for the first time. In addition to the 2017/18"/>
 <result pre="B/ Phuket/3073/2013-like virus (Yamagata lineage) was included. Influenza vaccination in" exact="Austria" post="is usually carried out between calendar weeks 40 to"/>
 <result pre="(&amp;lt;4% in our study population). Results Influenza Virus Activity in" exact="Austria" post="During the Seasons 2016/17 and 2018/19 As can be"/>
 <result pre="be seen in Figure 1, the three influenza seasons in" exact="Austria" post="differed significantly with regard to the circulating types and"/>
 <result pre="influenza season with an influenza incidence of 270,000 cases in" exact="Austria" post="and was characterized by the nearly exclusive circulation of"/>
 <result pre="analyzed by sequencing during this season. Vaccine Effectiveness Generally, in" exact="Austria" post="the influenza vaccine coverage is traditionally very low and"/>
 <result pre="years. Analyzing IVE for the QIVs, which were available in" exact="Austria" post="for the first time during this season, revealed a"/>
 <result pre="different European regions. In the northern parts of Europe, in" exact="Sweden" post="and Finland, the influenza season 2016/17 started early in"/>
 <result pre="proportion of circulating A(H3N2) genetic subclades in different regions. In" exact="Austria" post="3C.2a1 subclade accounted already for 71% of the circulating"/>
 <result pre="(16, 17). In this context, the low vaccine coverage in" exact="Austria" post="in contrast to that of the other European countries"/>
 <result pre="be taken into consideration. Nevertheless, detailed analyses of IVEs in" exact="Finland" post="and Sweden during the season showed a clear decline"/>
 <result pre="into consideration. Nevertheless, detailed analyses of IVEs in Finland and" exact="Sweden" post="during the season showed a clear decline in IVEs"/>
 <result pre="co-circulation of influenza B/Yamagata and A(H3N2) viruses was observed in" exact="Canada" post="(18). In Europe the majority of influenza viruses detected"/>
 <result pre="locally different proportions of co-circulating A(H1N1)pdm09 and/or A(H3N2) viruses. In" exact="Austria" post="influenza B viruses accounted for 67% of the circulating"/>
 <result pre="less no epidemic activity of the A(H3N2) viruses (4%). In" exact="Austria" post="the observed type-specific IVE of 45% against influenza B"/>
 <result pre="in Austria. This is in accordance with data described in" exact="Canada" post="(18), and differ to those obtained by the UK"/>
 <result pre="the LAIV against influenza B (61%) and A(H1N1)pdm09 (91%). In" exact="Austria" post="A good overall A(H1N1)pdm09 specific IVE of 66% and"/>
 <result pre="as this season was dominated by influenza A viruses. In" exact="Canada" post="(22) and Hong Kong (23) the 2018/19 influenza season"/>
 <result pre="was dominated by influenza A viruses. In Canada (22) and" exact="Hong Kong" post="(23) the 2018/19 influenza season was dominated by influenza"/>
 <result pre="genetic subclades, may also explain differences in IVE estimates. In" exact="Austria" post="influenza A(H1N1)pdm09 viruses dominated during the season 2018/19 accounting"/>
 <result pre="3C.2a1b, with a good match to the vaccine strain. In" exact="Austria" post="84% of the circulating A(H3N2) viruses belonged to the"/>
 <result pre="12.PebodyRWarburtonFEllisJAndrewsNPottsACottrellSet al.. End-of-season influenza vaccine effectiveness in adults and children," exact="United Kingdom," post="2016/17. Euro Surveill. (2017) 22:17-00306. 10.2807/1560-7917.ES.2017.22.44.17-0030629113630 13.SkowronskiDMChambersCSabaiducSDickinsonJAWinterALDe SerresGet al.."/>
 <result pre="season influenza vaccine effectiveness in adults and children in the" exact="United Kingdom" post="in 2017/18. Euro Surveill. (2019) 24:1800488. 10.2807/1560-7917.ES.2019.24.31.180048831387673 20.RondyMKisslingEEmborgHDGherasimAPebodyRTrebbienRet al.."/>
 <result pre="estimate of influenza vaccination effectiveness against influenza hospitalisation in children," exact="Hong Kong," post="winter influenza season 2018/19. Euro Surveill. (2019) 24:1900056. 10.2807/1560-7917.ES.2019.24.5.190005630722814"/>
</results>
